LianBio Reports Second Quarter 2023 Financial Results and Pr

Mavacamten New Drug Application (NDA) under priority review with China National Medical Products Administration (NMPA)Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpointData from EXPLORER-CN trial to be presented in an oral late-breaking science session at European Society of Cardiology Congress 2023Cash, cash equivalents and marketable securities of $267.3 million with runway into the first half of 2025

Related Keywords

China , Hong Kong , Macau , Madrid , Spain , United States , Taiwan , Singapore , Thailand , Shanghai , Macau Special Administrative Region , Macau General , Chinese , Asia Pacific , Josh Xu , Katherine Smith , Elizabeth Anderson , Pascal Qian , Yizhe Wang , Clinical Development Updates , China National Medical Products Administration , European Society Of Cardiology , Research Development Expenses , European Society Of Cardiology Congress , Chinese Cardiovascular Association , Exchange Commission , Tarsus Pharmaceuticals , Vp Communications , Astrazeneca , York Heart Association Class , Company Phase , Drug Administration , European Society Of Medical Oncology , Mavacamten New Drug Application , European Society , Cardiology Congress , Chief Executive Officer , Business Highlights , New York Heart Association Class , Macau Special Administrative , Chinese Demodex , Breakthrough Therapy Designation , Chief Commercial Officer , China General , Medical Oncology , Greater China , Annual Report , Months Ended June , Gastric Cancer , Clinical Trial , Phase 3 , Lianbio , Chinese Patients , Cm ,